Literature DB >> 7723747

Modulation by mu-opioid agonists of guanosine-5'-O-(3-[35S]thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells.

J R Traynor1, S R Nahorski.   

Abstract

The ability of mu-opioid agonists to activate G proteins has been demonstrated by studying the binding of the GTP analogue guanosine-5'-O-(3-[35S]thio)triphosphate ([35S]GTP gamma S) to membranes from the human neuroblastoma SH-SY5Y cell line. The potent opioid agonist fentanyl caused an approximate doubling of basal [35S]GTP gamma S binding in a naloxone-sensitive manner, confirming this to be an opioid receptor-mediated process. The presence of GDP was necessary to observe this effect. Pretreatment of the cells with pertussis toxin (100 ng/ml, for 24 hr) completely prevented the fentanyl-stimulated increase in [35S]GTP gamma S binding and lowered the basal binding of [35S]GTP gamma S. These latter data suggest an involvement of Gi and/or Go proteins and their activation by added membrane-bound receptors even in the absence of agonist. The order of potency of a series of opioid agonists in stimulating the binding of [35S]GTP gamma S was buprenorphine > cyclazocine = levallorphan > nalorphine > [D-Ala2,MePhe4,Gly-ol5]enkephalin (DAMGO) > fentanyl > morphine > pentazocine. DAMGO, fentanyl, and morphine were full agonists but the remaining compounds showed decreasing levels of intrinsic activity in the order buprenorphine > pentazocine > cyclazocine = nalorphine > levallorphan. The opioid antagonist naloxone was without effect. Under the conditions of the [35S]GTP gamma S assay, binding of agonists was to a high affinity site, indicating that a high agonist affinity state of the mu-opioid receptor is responsible for the observed stimulation of [35S]GTP gamma S binding. The level of [35S]GTP gamma S binding (597 fmol/mg of protein) stimulated by DAMGO was 2-fold greater than the maximal number of mu-opioid agonist binding sites (Bmax) determined using [3H]DAMGO (254 fmol/mg of protein). The opioid agonist-mediated stimulation of [35S]GTP gamma S binding in SH-SY5Y cell membranes thus provides a "functional" measure of agonist occupation of mu-opioid receptors and offers a simple method for the determination of efficacy and intrinsic activity of mu-opioid agonists.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7723747

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  113 in total

1.  Identification of the G-protein-coupled ORL1 receptor in the mouse spinal cord by [35S]-GTPgammaS binding and immunohistochemistry.

Authors:  M Narita; H Mizoguchi; D E Oji; N J Dun; B H Hwang; H Nagase; L F Tseng
Journal:  Br J Pharmacol       Date:  1999-11       Impact factor: 8.739

2.  Mu and Delta opioid receptors activate the same G proteins in human neuroblastoma SH-SY5Y cells.

Authors:  A Alt; M J Clark; J H Woods; J R Traynor
Journal:  Br J Pharmacol       Date:  2002-01       Impact factor: 8.739

3.  The enigma of morphine tolerance: recent insights.

Authors:  S B Ray; S Wadhwa
Journal:  J Biosci       Date:  2001-12       Impact factor: 1.826

4.  G-protein coupling of mu-opioid receptors (OP3): elevated basal signalling activity.

Authors:  N T Burford; D Wang; W Sadée
Journal:  Biochem J       Date:  2000-06-15       Impact factor: 3.857

5.  μ-opioid receptors: correlation of agonist efficacy for signalling with ability to activate internalization.

Authors:  Jamie McPherson; Guadalupe Rivero; Myma Baptist; Javier Llorente; Suleiman Al-Sabah; Cornelius Krasel; William L Dewey; Chris P Bailey; Elizabeth M Rosethorne; Steven J Charlton; Graeme Henderson; Eamonn Kelly
Journal:  Mol Pharmacol       Date:  2010-07-20       Impact factor: 4.436

6.  The first universal opioid ligand, (2S)-2-[(5R,6R,7R,14S)-N-cyclopropylmethyl-4,5-epoxy-6,14-ethano-3-hydroxy-6-methoxymorphinan-7-yl]-3,3-dimethylpentan-2-ol (BU08028): characterization of the in vitro profile and in vivo behavioral effects in mouse models of acute pain and cocaine-induced reward.

Authors:  Taline V Khroyan; Willma E Polgar; Gerta Cami-Kobeci; Stephen M Husbands; Nurulain T Zaveri; Lawrence Toll
Journal:  J Pharmacol Exp Ther       Date:  2010-12-21       Impact factor: 4.030

7.  Development and in vitro characterization of a novel bifunctional μ-agonist/δ-antagonist opioid tetrapeptide.

Authors:  Lauren C Purington; Katarzyna Sobczyk-Kojiro; Irina D Pogozheva; John R Traynor; Henry I Mosberg
Journal:  ACS Chem Biol       Date:  2011-10-11       Impact factor: 5.100

8.  A Novel and Selective Nociceptin Receptor (NOP) Agonist (1-(1-((cis)-4-isopropylcyclohexyl)piperidin-4-yl)-1H-indol-2-yl)methanol (AT-312) Decreases Acquisition of Ethanol-Induced Conditioned Place Preference in Mice.

Authors:  Nurulain T Zaveri; Paul V Marquez; Michael E Meyer; Willma E Polgar; Abdul Hamid; Kabirullah Lutfy
Journal:  Alcohol Clin Exp Res       Date:  2018-01-19       Impact factor: 3.455

9.  Potent inhibition of alcohol self-administration in alcohol-preferring rats by a κ-opioid receptor antagonist.

Authors:  John R Cashman; Marc R Azar
Journal:  J Pharmacol Exp Ther       Date:  2014-05-09       Impact factor: 4.030

10.  Differential modulation of mu-opioid receptor signaling to adenylyl cyclase by regulators of G protein signaling proteins 4 or 8 and 7 in permeabilised C6 cells is Galpha subtype dependent.

Authors:  Jeffery N Talbot; David L Roman; Mary J Clark; Rebecca A Roof; John J G Tesmer; Richard R Neubig; John R Traynor
Journal:  J Neurochem       Date:  2009-11-30       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.